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Introduction: The number of infections due to uncommon yeast species is gradually increasing
worldwide. In cases of high-risk paediatric patients, Cyberlindnera fabianii has been identified
as the causal agent in a number of countries. In fact, we have recently reported the first proven
occurrence, to the best of our knowledge, of this species as a causal agent of fungaemia in
three neonatal patients in a Croatian hospital.
Case presentation: We report here six new instances of clinically manifested bloodstream and
urinary tract infections caused by Cyberlindnera fabianii in five high-risk neonates and one
child, during a 5-year period (2008–2012) in the aforementioned Croatian hospital. In addition,
we have provided an account of their treatment strategy and the outcome, and the
susceptibility profiles of 44 isolates of Cyberlindnera fabianii to amphotericin B, flucytosine,
triazoles and echinocandins. Furthermore, we have described a novel molecular method
suitable for the rapid and specific diagnosis of this species.
Conclusion: Our findings demonstrated: (i) the pathogenic activities of Cyberlindnera fabianii
species in high-risk children; (ii) that administering fluconazole either prophylactically or
therapeutically yielded no results in 50 % of the patients; (iii) that substituting fluconazole by
liposomal amphotericin B or caspofungin managed to resolve sepsis in the remaining 50 % of
patients; (iv) that, according to the examined sequences, all of the Cyberlindnera fabianii
isolates were found to be identical independent of their source or study period; and (v) the
existence of a higher proportion of non-susceptible isolates of Cyberlindnera fabianii for
echinocandins (especially micafungin) compared with the other tested antifungals.
Keywords: amphotericin B, caspofungin; Cyberlindnera infections; fungaemia; fluconazole;
funguria; immunocompromised children.
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Introduction
Infections caused by rare Candida spp. have become
increasingly common in high-risk patients within hospital
settings (Valenza et al., 2006; Wu et al., 2013). Among
these, Cyberlindnera fabianii, the teleomorph of Candida
fabianii (Freel et al., 2014), has been reported by a few
researchers as the causative agent of various infections
(Bhally et al., 2006; Valenza et al., 2006; Gabriel et al.,
2012; Wu et al., 2013; Yun et al., 2013). In addition, we
have previously described three cases of clinically mani-
fested fungaemia in neonatal patients caused by Cyberlind-
nera fabianii[Q1], initially misidentified as Candida utilis
(Lukic´-Grlic´ et al., 2011). From 2008 to 2012, Cyberlind-
nera fabianii was isolated from various clinical samples of
another six patients hospitalized in the neonatal intensive
care unit (NICU) and paediatric intensive care unit
Abbreviations: CASPO, caspofungin; CRP, C-reactive protein; CVC,
central venous catheter; ELBW, extremely low birth weight; EUCAST,
European Committee on Antimicrobial Susceptibility Testing; FLU,
fluconazole; ICI, invasive Candida infection; i.v., intravenous; lAMB,
liposomal amphotericin B; NICU, neonatal intensive care unit; PICU,
paediatric intensive care unit.
The GenBank/EMBL/DDBJ accession numbers for the Cyberlindnera
fabianii sequences determined in this study are KM384023–
KM384033.
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(PICU) of our hospital (Children’s Hospital Zagreb,
Zagreb, Croatia). The sporadic occurrence of this yeast
over a longer period (5 years) in an increased number of
patients was the reason for the detailed analysis and the
subsequent presentation of clinical, diagnostic, prophylac-
tic and therapeutic data.
Case report
Case 1
The patient was a 3-and-a-half-year-old girl hospitalized in
the PICU of the Children’s Hospital in Zagreb, in the
autumn of 2008, 5 months after receiving her last cycle
of chemotherapy for acute lymphoblastic leukaemia. She
was admitted to the hospital with high fever, a high C-reac-
tive protein (CRP) level and a low white blood cell count.
Extended-spectrum antibiotic therapy commenced
(without any detected micro-organisms) and after 5 days
fluconazole (4 mg kg21 orally) was added to the treatment.
On day 20 of hospitalization, the patient’s condition wor-
sened (fever of 38.5 uC accompanied by chills and vomit-
ing). Laboratory findings manifested an elevated level of
CRP (24 mg l21) and mild thrombocytopenia
(70|109 l21). A non-albicans Candida sp. was isolated
from blood culture, as well as from a stool sample. The flu-
conazole dosage was increased to 6 mg kg21 intravenously
(i.v.). As the blood culture taken 5 days later was still posi-
tive for the same yeast, fluconazole was substituted with
liposomal amphotericin B (3 mg kg21) (Table 1). After
3 days of amphotericin B therapy, there was a noticeable
clinical improvement and the blood culture became sterile.
The same therapy was continued for a further 11 days.
Case 2
In November 2009, a 1.5-month-old male infant was
admitted to our hospital with bilateral hydronephrosis,
vesicoureteral reflux grade IV and a posterior urethral
valve. Ten days after his arrival, he was transferred to
PICU due to urosepsis. Extended-spectrum b-lactamase-
producing Klebsiella pneumoniae was isolated only from
the urine sample, warranting the introduction of merope-
nem (20 mg kg21) to the therapy. A control urine sample
taken a few days later tested positive for non-albicans Can-
dida sp. Fluconazole (6 mg kg21 orally) was added to the
therapy and he was transferred to the Department of Urol-
ogy. After another 5 days, the patient became febrile with a
CRP level of 21 mg l21 and white blood cell count of
14.6|109 l21, and he was again admitted to the PICU.
The same yeast species was again isolated from a urine
sample, and fluconazole (6 mg kg21) was given intrave-
nously. After 48 h, clinical stabilization was brought
about, prompting a surgical operation the next day (resec-
tion of the posterior urethral valve and suprapubic Cysto-
fix cystostomy). The last positive urine sample was taken
on day 8 after surgical treatment. Fluconazole was admi-
nistered for a total of 27 days (Table 1). T
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Case 3
In May 2011, a female newborn with a birth weight of
3470 g, born in week 38 of gestation, was hospitalized in
the NICU with gastroschisis. Operative treatment com-
menced on the same day, beginning with antibiotic pro-
phylaxis (ampicillin and gentamycin). The day after she
became febrile, her CRP level increased to 123 mg l21.
Blood cultures were taken, and gentamycin was replaced
with meropenem (20 mg kg21) along with the addition
of metronidazole. Blood cultures proved to be sterile.
On day 12 of hospitalization, the symptoms of sepsis devel-
oped again with a CRP level of 101 mg l21. Blood cultures,
urine samples and nasopharyngeal aspirate were taken; the
central venous catheter (CVC) was removed, and vanco-
mycin, piperacillin-tazobactam and fluconazole (6 mg
kg21 i.v.) were added to the therapy. Blood cultures and
the nasopharyngeal aspirate were positive for Chryseobac-
terium indologenes. Non-albicans Candida sp. was isolated
from the urine and aspirate samples. Subsequently, the
same dose of fluconazole was continued (6 mg kg21 i.v.)
for a period of 27 days (Table 1). A urine sample taken
on day 17 of hospitalization was sterile.
Case 4
A male newborn weighing 2900 g, born in week 36 of ges-
tation, was hospitalized in the NICU with bilateral ureter-
ohydronephrosis, a posterior urethral valve and
vesicoureteral reflux grade IV in October 2011. On day
10 of hospitalization, he became septic. Blood cultures
and urine were taken, and antibiotic therapy (meropenem)
was started. Non-albicans Candida sp. was isolated only
from the urine sample. Fluconazole at a reduced dose
(3 mg kg21 i.v., because of decreased renal function) was
applied. On day 15 of hospitalization, due to the pro-
gression of ureterohydronephrosis, the surgical procedure
of ureterocutaneostomy had to be performed. During the
next 3 weeks, in spite of fluconazole therapy, we were able
to collect 24 more non-albicans Candida sp. isolates from
different clinical and environmental samples (Table 1).
During that time, screening tests for dissemination of
fungal infection proved negative, so the fluconazole therapy
was continued for 30 days in total. On day 45 of his life, he
was septic again; his CRP level was 31 mg l21 and white
blood cell count was 14.27|109 l21. As the same yeast per-
sisted in the urine samples, a reduced dosage of caspofungin
(1.0 mg kg21 i.v.) was applied for the next 10 days (Table 1)
until the urine became sterile.
Case 5
In September 2012 a female neonate (40 weeks of ges-
tation, 3730 g of body weight) was hospitalized in the
NICU after undergoing a surgical procedure due to an
intestinal atresia. She was on parenteral nutrition and
anti-ulcer prophylaxis, and was receiving antibiotic therapy
(ampicillin and gentamycin for 6 days). Because of the
presence of extended-spectrum b-lactamase-producing
K. pneumoniae in nasopharyngeal swab and stool samples,
the initial antibiotic therapy was [Q2]changed to merope-
nem. On day 5 of hospitalization in the NICU, non-albi-
cans Candida sp. was isolated from the stool and gastric
content, and fluconazole (6 mg kg21 i.v.) was introduced
to the therapy. On day 22, she became septic, with a
fever of 38.7 uC and CRP level of 30 mg l21. Non-albicans
Candida sp. and meticillin-resistant Staphylococcus epider-
midis were isolated from two blood cultures obtained on
the same day. As a result, the CVC was removed, whilst
vancomycin (15 mg kg21) every 6 h for 7 days and fluco-
nazole (12 mg kg21 i.v.) for 15 days were applied (Table 1).
Case 6
In September 2012, at the same time as the patient
described in case 5, a female premature infant, born after
24 weeks of gestation and with an extremely low birth
weight (ELBW) of 740 g, was admitted to our NICU on
day 10 of her life because of a large cyst in her lungs.
Upon admittance, she was already on antibiotic therapy
(ampicillin and gentamycin) and antifungal prophylaxis
(fluconazole 5 mg kg21 i.v. every 72 h). On day 25, after
the cessation of fluconazole prophylaxis, a non-albicans
Candida sp. was isolated from the aspirate of an endotra-
cheal tube. Fluconazole (6 mg kg21 i.v. every 48 h) was
again instituted as therapy, but after 2 days the infant’s
fever rose drastically to 38.5 uC, her CRP level increased
to 30 mg l21 and the thrombocyte count decreased to
45|109 l21. Blood cultures, as well as other clinical speci-
mens, were taken for bacteriological and mycological
examination. The same yeast was isolated from three
blood cultures (on alternate days over a 5-day span) and
from the oral cavity. Fluconazole was replaced with caspo-
fungin (2 mg kg21) for the next 3 weeks (Table 1).
Investigations
In vitro antifungal susceptibility testing was performed
using the ATB FUNGUS 3 (bioMe´rieux,) microdilution
method, and the results were interpreted according to
European Committee on Antimicrobial Susceptibility
Testing (EUCAST) recommendations. No in vitro resist-
ance to amphotericin B, flucytosine, fluconazole, itraco-
nazole or voriconazole was observed. Of the three
echinocandins, only caspofungin was available in Croatia
during the observed period (anidulafungin was registered
in 2013 and micafungin in 2014); however, EUCAST
breakpoints had not yet been established for caspofun-
gin. Therefore, the susceptibility testing of all isolates
for echinocandins was done later using Etest (Liofil-
chem). MIC values showed variation among the isolates
to a certain degree; however, they were the lowest for
anidulafungin (0.016–0.064 mg l21), higher for caspo-
fungin (0.125–0.19 mg l21) and highest for micafungin
(1–4 mg l21).
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Diagnosis
A total of 44 isolates were recovered from various speci-
mens of the six patients on Sabouraud glucose agar
(Tables 1 and 2) and were ultimately identified using an
API ID 32C kit (bioMe´rieux) and on the basis of cornmeal
agar morphology as Candida utilis.
The identity of 11 selected isolates was checked by the PCR
amplification, sequencing and sequence analysis of a frag-
ment of the rRNA gene region (Kocsube´ et al., 2007)
(Table 2). Amplification was performed using the universal
primers ITS1 and ITS4 (White et al., 1990) targeting the
internal transcribed spacer (ITS) of the ribosomal gene
cluster. Based on the sequence data, all 11 isolates were
re-identified as Cyberlindnera fabianii (Table 2). Phyloge-
netic reconstruction was conducted using raxmIGUI
v.1.3 under the GTR+G model (Silvestro & Michalak,
2011). The analysis was run with 1000 bootstrap replicates.
The ITS sequences of the isolates were found to be identi-
cal, showing no genetic differences among the strains
(Fig. 1). Based on a species-specific sequence of the
rRNA gene region of Cyberlindnera fabianii, a species-
specific primer (59-TGCGTGGAATAAGCCTAGCT-39)
was designed to be used in combination with the
common ITS4 primer for identification of the rest of the
isolates. The reaction mixture contained 2 ml 10| Taq
buffer with KCl (Thermo Scientific), 2 ml MgCl2
(25 mM), 4 ml dNTP mix (2 mM each), 4 ml of each
primer (1 mM each), 3 ml ddH2O, 0.1 ml Taq DNA poly-
merase (5 U ml21) and 1 ml template DNA.
An approximately 510 bp fragment was amplified using
one cycle of 94 uC for 3 min, 35 cycles of 94 uC for 20 s,
48 uC for 15 s and 72 uC for 40 s, and one cycle of 72 uC
for 2 min. The newly developed PCR-based method
proved to be suitable for the rapid and specific detection
and identification of Cyberlindnera fabianii. With this
new approach, the identity of all the isolates reported in
this study was confirmed as Cyberlindnera fabianii (Fig. 2).
Discussion
We have presented the cases of six patients who were hos-
pitalized in the NICU and PICU over a period of 5 years
(2008–2012) with Cyberlindnera fabianii isolated from var-
ious clinical specimens.
Cyberlindnera fabianii has been described as a causative
agent of infections both in infants and adults (Bhally
et al., 2006; Valenza et al., 2006; Gabriel et al., 2012; Wu
et al., 2013). Using commercial yeast diagnostic kits, such
as API 20C AUX, ID32C and Vitek-2, these isolates have
frequently been misidentified (Valenza et al., 2006; Gabriel
et al., 2012). After three incidences of Candida utilis candi-
daemia in our NICU in 2008 (Lukic´-Grlic´ et al., 2011), 42
other isolates were collected from six other patients with
fungaemia or funguria, along with two environmental spe-
cimens. All isolates were re-identified as Cyberlindnera
fabianii (teleomorph of Candida fabianii) by analysis of
their ITS sequences, as well as by the novel, PCR-based
technique described above. This method proved to be suit-
able for rapid and specific diagnosis, verifying in turn that
all of the examined Cyberlindnera isolates belonged to this
uncommon species.
The process of predicting possible risks for patients in the
NICU and PICU of developing invasive Candida infections
(ICI) poses a crucial challenge. By combining various risk
factors, it has been shown that the risk of ICI in these
patients ranges from 10 to 46 % (Zaoutis et al., 2010; Bris-
saud et al., 2012). All of our six patients had different risk
factors: one was a premature infant with ELBW
(v1000 g), another one was a child with leukaemia and
neutropenia, three of them underwent surgical procedure,
and all were on parenteral nutrition and antibiotic therapy
(Table 1). There are around 400 patients hospitalized in
our hospital’s PICU every year, whilst 50 patients get
admitted to the NICU. During the described period, the
incidence of ICI in the NICU was 4 %, whilst it was only
0.5 % in PICU patients. The most often detected causative
agent in NICU patients was Cyberlindnera fabianii followed
by Candida albicans, whereas Candida albicans was the
leading causative agent of ICI in the PICU. Decisions for
implementing antifungal prophylaxis were made on an
individual basis so that ultimately three of our patients
received it (Table 1). After the isolation of Cyberlindnera
fabianii, fluconazole therapy was initiated, whilst liposomal
amphotericin B was continued in one patient and caspo-
fungin in the remaining two (Table 1). From 2013 until
now, the yearly incidence of ICI in the NICU has been
reduced to 2 %. Whilst Candida guilliermondii caused the
only case of ICI in 2013, Candida albicans was responsible
for the single ICI in 2014.
Candidaemia in children caused by Cyberlindnera fabianii
has been described in a few publications (Bhally et al.,
2006; Hamal et al., 2008; Grenouillet et al., 2010; Lukic´-
Grlic´ et al., 2011; Wu et al., 2013). In this paper, we present
not only three more cases of fungaemia but also three cases
of funguria caused by Cyberlindnera fabianii. Until now,
Table 2. GenBank accession numbers of the ITS sequences
of Cyberlindnera fabianii isolates from the presented cases
Case Isolate Origin GenBank
accession number
1 CfZg 10 Stool KM384032
2 CfZg 17 Urine KM384031
3 CfZg 20 Nasopharyngeal swab KM384030
4 CfZg 25 Left urostoma KM384029
4 CfZg 26 Wound around left urostoma KM384028
4 CfZg 32 Air above the child KM384027
4 CfZg 33 Air inside the respirator KM384026
4 CfZg 45 Right urostoma KM384025
5 CfZg 51 Gastric content KM384024
6 CfZg 52 Tubal aspirate KM384023
6 CfZg 55 Swab of buccal cavity KM384033
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there has only been one paper, to the best of our knowledge,
reporting Cyberlindnera fabianii candiduria (presented as
prostatitis) in a 57-year-old male patient with chronic
lymphatic leukaemia (Dooley et al., 1990). In critically ill
children, urinary tract abnormalities, use of a urinary
catheter, prior dialysis, total parenteral nutrition, use of a
vascular catheter, artificial ventilation and duration of
therapy with broad-spectrum antibiotics are associated
with candiduria (Trnka et al., 1998). According to the
literature, candiduria develops in approximately 2.4 % of
very low birth weight (v1500 g) infants and up to 6 % of
ELBW (v1000 g) infants (Kaufman & Fairchild, 2004).
European Society of Clinical Microbiology and Infectious
Diseases (ESCMID) guidelines recommend fluconazole pro-
phylaxis for the prevention of ICI in neonates, whilst for
therapeutic options they propose various formulations of
amphotericin B, fluconazole, caspofungin and micafungin
Fig. 1. Maximum-likelihood tree based on the ITS sequences of Cyberlindnera/Candida fabianii isolates reported in the pre-
sent study. Numbers above branches are bootstrap values. Only values above 70 % are indicated.
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(Hope et al., 2012). Among our patients, the prophylactic
application of fluconazole was not successful in preventing
ICI. However, fluconazole treatment (with removal
of the CVC and/or urinary catheters) or substituting fluco-
nazole with liposomal amphotericin B or caspofungin led
to clinical resolution and elimination of Cyberlindnera
fabianii from the blood or urine (during the time of
the treatment, micafungin had not yet been registered in
Croatia).
The attributable mortality of candidaemia in children has
been reported to be 10 % (Zaoutis et al., 2010). Grenouillet
et al. (2010) described a case of Cyberlindnera fabianii can-
didaemia in an ELBW pre-term infant with a fatal out-
come. Rather limited information can be found in the
literature pertaining to the prognosis of candidal urinary
tract infections in infants in the NICU. Robinson et al.
(2009), in a study of the characteristics and outcome of
infants with candiduria, found the mortality of 30 % to
be linked with Candida infection, suggesting the need for
antifungal therapy with repeated evaluation for dissemina-
tion in those infants who are slow to respond to therapy.
Studies have demonstrated a similar mortality rate in
infants with Candida urinary tract infection alone
(26 %), compared with Candida bloodstream infections
(28 %) in ELBW infants (Wynn et al., 2012).
A multidisciplinary approach to high-risk patients with
accurate microbiological diagnosis, strict implementation
of infection control measures and intensive care manage-
ment of the septic infant all had a decisive effect on secur-
ing a successful outcome of Cyberlindnera fabianii
infection in our patients. Future efforts should focus on
the validation of risk factors identified in our NICU popu-
lation and on the development of interventions for pre-
venting a high incidence of Cyberlindnera fabianii
infections.
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